Form 4: Senti Biosciences Director Fran Schulz Acquires Stock Options

Director Fran Schulz acquired 43,900 stock options in Senti Biosciences on March 7, 2025, at an exercise price of $3.52.

Summary

• Fran Schulz, a director of Senti Biosciences, Inc. (SNTI), acquired 43,900 stock options on March 7, 2025.
• The exercise price of these options is $3.52.
• The options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• The expiration date for the options is March 6, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction filing. The acquisition of options by a director is generally viewed as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates